Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | SLC40A1 | Q9NP59 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13578092 | 0.87 | SMN1; SMN2 (0.43) | ADORA2ACNR2SMN1; SMN2 | |
| SCHEMBL13578095 | 0.85 | TP53 (0.47) | CNR2SMN1; SMN2 | |
| SCHEMBL13578097 | 0.84 | ALDH1A1 (0.55) | CNR2SMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL4341463 | 0.83 | SMN1; SMN2 (0.40) | CNR2SMN1; SMN2 | |
| SCHEMBL13578102 | 0.83 | ALDH1A1 (0.51) | CNR2SMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL4327011 | 0.81 | TP53 (0.44) | ADORA2AADORA1CNR2 | |
| Trifluoroacetic Acid SCHEMBL4321817 | 0.79 | KDM4E (0.47) | CNR2SMN1; SMN2 | |
| SCHEMBL13578100 | 0.79 | TP53 (0.51) | CNR2SMN1; SMN2 | |
| SCHEMBL13578096 | 0.79 | KMT2A (0.51) | ADORA2ASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL4326435 | 0.79 | ALDH1A1 (0.50) | CNR2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | CNR2, CNR1, TRPV1 | ADORA2A 127/4885ADORA1 164/4885CNR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.